Toshiba has announced that the FDA cleared its Superb Micro-Vascular Imaging (SMI) technology to be used with the company’s Aplio 500 ultrasound system. SMI technology allows for imaging of low velocity blood microvasculature using only ultrasound. Previously physicians were limited to using contrast agents or invasive methods to visualize blood flow around tumors, lymph nodes, and other points of interest.
“Toshiba ultrasound continues to push the envelope,” said Tomohiro Hasegawa, director, Toshiba’s Ultrasound Business Unit in a statement. “With the development of SMI, clinicians can provide the right diagnosis on all patients earlier for improved care. Additionally, SMI expands the utility of ultrasound, which results in fewer ionizing procedures, improving patient safety.”
Product page: Superb Micro-Vascular Imaging (SMI)…
Announcement: Toshiba’s New Technology Enables Blood Flow Visualization Never Thought Possible with Ultrasound…